EGFR and neoplasm: In a study by Buck et al., CRC cell lines derived from the same patient showed epithelial characteristics and sensitivity to EGFR tyrosine kinase inhibitor erlotinib in cells from the primary tumour, whereas tumour cells from the liver metastasis exhibited a mesenchymal phenotype and were not sensitive to erlotinib [54].